New diabetes drug tested in patients with liver disease
NCT ID NCT07193147
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 23 times
Summary
This study tests a single dose of an investigational diabetes drug called GZR4 in 36 adults with diabetes who also have mild, moderate, or severe liver impairment. The goal is to see how the drug moves through the body and whether it is safe in people with different levels of liver function. Participants receive one injection and are monitored for side effects and drug levels over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Gan & Lee Pharmaceuticals Shandong Co., Ltd.
Linyi, Shandong, 276000, China
Conditions
Explore the condition pages connected to this study.